carmustine has been researched along with Thrombopenia in 47 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)." | 9.05 | Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982) |
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 9.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])." | 7.66 | Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982) |
| "The outcome after treatment for glioblastoma remains poor." | 6.69 | Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998) |
| "Thrombocytopenia was the most frequent form of toxicity." | 6.65 | Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. ( Alexanian, R; Amare, M; Bonnet, J; Bottomley, R; Dixon, D; Haut, A; Salmon, S, 1982) |
| "Autologous stem cell transplantation after high-dose melphalan for the treatment with multiple myeloma has resulted in prolonged progression-free survival and overall survival in patients under 65 years." | 5.09 | The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. ( Bhagwati, N; Horton, C; Kulkarni, S; Mainwaring, P; Mehta, J; Pandha, H; Powles, R; Singhal, S; Sirohi, B; Treleaven, J, 2000) |
| "Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)." | 5.05 | Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982) |
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 5.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "A retrospective study of 30 cases of Hodgkin disease in patients who underwent high-dose carmustine, etoposide, and cyclophosphamide chemotherapy with PBSC support was performed." | 3.70 | Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin disease. ( Bogart, JA; Chung, CT; Ryu, S; Ungureanu, C; Zamkoff, KW, 2000) |
| "21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks." | 3.67 | Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984) |
| "High-dose chemotherapy with BCNU, melphalan, or both, followed by autologous bone marrow transplantation (ABMT) has been reported to produce response rates in excess of 60% in patients with advanced melanoma." | 3.67 | High-dose chemotherapy without autologous bone marrow transplantation in melanoma. ( Aisner, J; Tait, N; Tchekmedyian, NS; Van Echo, D, 1986) |
| "Twenty-three patients with metastatic melanoma were treated with combination therapy consisting of dacarbazine (220 mg/m2) and cisplatin (25 mg/m2) iv daily for 3 days every 3 weeks, carmustine (150 mg/m2) iv every 6 weeks, and tamoxifen (10 mg) orally twice daily." | 3.67 | Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF, 1987) |
| "From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])." | 3.66 | Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982) |
| " Pharmacokinetic evaluation was done on the first cycle (one dose was given intravenously on day 1 or 5 of the first cycle to determine bioavailability)." | 2.71 | SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. ( Alaoui-Jamali, M; Bangash, N; Batist, G; Melnychuk, D; Miller, WH; Panarello, L; Panasci, L; Patenaude, F; Sandor, V; Sausville, E; Stinson, SF, 2003) |
| " The distribution of adverse prognostic factors was comparable in the two-induction arm." | 2.70 | Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. ( Bernard, M; Casassus, P; Delain, M; Desablens, B; Guilhot, F; Hunault-Berger, M; Ifrah, N; Jouet, JP; Milpied, N; Sadoun, A, 2001) |
| " The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days." | 2.70 | Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. ( Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S, 2001) |
| "The outcome after treatment for glioblastoma remains poor." | 2.69 | Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998) |
| "Fifty-eight patients with previously untreated multiple myeloma were entered." | 2.68 | Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma. ( Gregory, SA; Greipp, PR; Kay, NE; Kyle, RA; O'Connell M, J; Oken, MM; Spiegel R, J; Tsiatis, A, 1996) |
| " The dosage of CCNU was 100 mg/m2 p." | 2.65 | The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. ( Brunner, K; Cuttner, J; Falkson, G; Hansen, HH; Holland, JF; Nissen, NI; Pajak, TF; Selawry, OS; Spurr, CL, 1981) |
| "Thrombocytopenia was the most frequent form of toxicity." | 2.65 | Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. ( Alexanian, R; Amare, M; Bonnet, J; Bottomley, R; Dixon, D; Haut, A; Salmon, S, 1982) |
| "It is an effective drug in the treatment of malignant melanoma with better response rates in women than in men." | 2.64 | Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. ( Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W, 1976) |
| "One patient had a retinal vein thrombosis." | 2.39 | Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. ( Baars, JW; de Glas-Vos, CW; Rodenhuis, S; Thomas, BL; van der Lelie, H; van Dijk, MA; van Oers, RH; von dem Borne, AE, 1995) |
| "Fourteen (26%) patients with Hodgkin's lymphoma and 40 (74%) patients with non-Hodgkin's lymphoma were analyzed." | 1.36 | Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. ( Buset, EM; Haile, SR; Honegger, H; Knuth, A; Mischo, A; Pestalozzi, BC; Petrausch, U; Renner, C; Samaras, P; Schanz, U; Siciliano, RD; Stahel, RA; Stenner-Liewen, F; Stussi, G, 2010) |
| "Mini-BEAM/HSC is an effective treatment for lymphoma relapses after allogeneic HSCT, but optimal strategies of remission consolidation and prevention of treatment-related complications are needed to improve outcome." | 1.32 | Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor. ( Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL, 2003) |
| "Fatal leukoencephalopathy occurred in two patients." | 1.27 | Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme. ( Bashir, R; Hochberg, FH; Hottleman, K; Linggood, RM, 1988) |
| "Thirty patients with relapsed Hodgkin's disease were treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) and autologous bone marrow transplantation." | 1.27 | High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. ( Armitage, JO; Cabanillas, FF; Dicke, KA; Horwitz, LJ; Jagannath, S; Spitzer, G; Vellekoop, L; Zander, AR, 1986) |
| "Skin, lymph node, and soft tissue metastases more frequently responded to therapy, while hepatic, peritoneal, and osseous metastases responded with an intermediate frequency." | 1.26 | Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma. ( Klahr, C; Presant, CA; Van Amburg, A, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (57.45) | 18.7374 |
| 1990's | 7 (14.89) | 18.2507 |
| 2000's | 11 (23.40) | 29.6817 |
| 2010's | 2 (4.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Samaras, P | 1 |
| Buset, EM | 1 |
| Siciliano, RD | 1 |
| Haile, SR | 1 |
| Petrausch, U | 1 |
| Mischo, A | 1 |
| Honegger, H | 1 |
| Pestalozzi, BC | 1 |
| Schanz, U | 1 |
| Stussi, G | 1 |
| Stahel, RA | 1 |
| Knuth, A | 1 |
| Renner, C | 1 |
| Stenner-Liewen, F | 1 |
| Noël, G | 1 |
| Schott, R | 1 |
| Froelich, S | 1 |
| Gaub, MP | 1 |
| Boyer, P | 1 |
| Fischer-Lokou, D | 1 |
| Dufour, P | 1 |
| Kehrli, P | 1 |
| Maitrot, D | 1 |
| Panasci, L | 1 |
| Stinson, SF | 1 |
| Melnychuk, D | 1 |
| Sandor, V | 1 |
| Miller, WH | 1 |
| Batist, G | 1 |
| Patenaude, F | 1 |
| Bangash, N | 1 |
| Panarello, L | 1 |
| Alaoui-Jamali, M | 1 |
| Sausville, E | 1 |
| Arellano-Rodrigo, E | 1 |
| López-Guillermo, A | 1 |
| Bessell, EM | 1 |
| Nomdedeu, B | 1 |
| Montserrat, E | 1 |
| Graus, F | 1 |
| Au, WY | 1 |
| Lie, AK | 1 |
| Siu, LL | 1 |
| Chan, EC | 1 |
| Ooi, GC | 1 |
| Leung, AY | 1 |
| Liang, R | 1 |
| Kwong, YL | 1 |
| Decaudin, D | 1 |
| Vantelon, JM | 1 |
| Bourhis, JH | 1 |
| Farace, F | 1 |
| Bonnet, ML | 1 |
| Guillier, M | 1 |
| Greissenger, N | 1 |
| Marracho, MC | 1 |
| Assari, S | 1 |
| Bennaceur, AL | 1 |
| Némati, F | 1 |
| Michon, J | 1 |
| Turhan, AG | 1 |
| Boccaccio, C | 1 |
| Hua, XM | 1 |
| Ren, XW | 1 |
| Liu, FL | 1 |
| Liu, Y | 1 |
| Zhang, CJ | 1 |
| Li, ZJ | 1 |
| Xu, L | 1 |
| Liu, JY | 1 |
| Liu, YG | 1 |
| Ryan, CW | 1 |
| Dolan, ME | 2 |
| Brockstein, BB | 1 |
| McLendon, R | 1 |
| Delaney, SM | 1 |
| Samuels, BL | 1 |
| Agamah, ES | 1 |
| Vokes, EE | 1 |
| Stewart, DJ | 1 |
| Benoit, B | 1 |
| Richard, MT | 1 |
| Hugenholtz, H | 1 |
| Dennery, J | 1 |
| Russell, N | 1 |
| Peterson, E | 1 |
| Grahovac, Z | 1 |
| Belanger, G | 1 |
| Maroun, JA | 1 |
| Seigler, HF | 1 |
| Lucas, VS | 1 |
| Pickett, NJ | 1 |
| Huang, AT | 1 |
| Robustelli della Cuna, G | 1 |
| Paoletti, P | 1 |
| Bernardo, G | 1 |
| Knerich, R | 1 |
| Butti, G | 1 |
| Cuzzoni, Q | 1 |
| Oken, MM | 2 |
| Costello, WG | 1 |
| Johnson, GJ | 1 |
| Lenhard, RE | 1 |
| Ezdinli, EZ | 1 |
| Orlow, E | 1 |
| Barnes, JM | 1 |
| Berard, CW | 1 |
| Glick, JH | 1 |
| DiBella, NJ | 1 |
| Garfield, D | 1 |
| Fink, K | 1 |
| Anderson, P | 1 |
| Speer, J | 1 |
| Murphy, J | 1 |
| Kempin, S | 1 |
| Lee, BJ | 1 |
| Thaler, HT | 1 |
| Koziner, B | 1 |
| Hecht, S | 1 |
| Gee, T | 1 |
| Arlin, Z | 1 |
| Little, C | 1 |
| Straus, D | 1 |
| Reich, L | 1 |
| Phillips, E | 1 |
| Al-Mondhiry, H | 1 |
| Dowling, M | 1 |
| Mayer, K | 1 |
| Clarkson, B | 1 |
| Tirelli, U | 1 |
| Crivellari, D | 1 |
| Carbone, A | 1 |
| Veronesi, A | 1 |
| Galligioni, E | 1 |
| Trovò, MG | 1 |
| Tumolo, S | 1 |
| Grigoletto, E | 1 |
| Hansen, HH | 1 |
| Selawry, OS | 1 |
| Pajak, TF | 3 |
| Spurr, CL | 1 |
| Falkson, G | 1 |
| Brunner, K | 3 |
| Cuttner, J | 2 |
| Nissen, NI | 1 |
| Holland, JF | 2 |
| Bonnet, J | 1 |
| Alexanian, R | 1 |
| Salmon, S | 1 |
| Bottomley, R | 1 |
| Amare, M | 1 |
| Haut, A | 1 |
| Dixon, D | 1 |
| Kyle, RA | 3 |
| Henderson, ES | 1 |
| Nawabi, IU | 1 |
| Henry, PH | 1 |
| McIntyre, OR | 2 |
| Cornwell, GG | 1 |
| Kochwa, S | 1 |
| Glowienka, LP | 1 |
| Rafla, S | 1 |
| Silver, RT | 1 |
| Cooper, MR | 1 |
| Henderson, E | 1 |
| Haurani, FI | 1 |
| Mitchell, RB | 1 |
| Janisch, L | 1 |
| Vogelzang, NJ | 1 |
| Ratain, MJ | 1 |
| Schilsky, RL | 1 |
| van der Lelie, H | 1 |
| Baars, JW | 1 |
| Rodenhuis, S | 1 |
| van Dijk, MA | 1 |
| de Glas-Vos, CW | 1 |
| Thomas, BL | 1 |
| van Oers, RH | 1 |
| von dem Borne, AE | 1 |
| Greipp, PR | 1 |
| Kay, NE | 1 |
| Tsiatis, A | 1 |
| Gregory, SA | 1 |
| Spiegel R, J | 1 |
| O'Connell M, J | 1 |
| Brandes, AA | 1 |
| Rigon, A | 1 |
| Zampieri, P | 1 |
| Ermani, M | 1 |
| Carollo, C | 1 |
| Altavilla, G | 1 |
| Turazzi, S | 1 |
| Chierichetti, F | 1 |
| Florentino, MV | 1 |
| Kleinberg, L | 1 |
| Grossman, SA | 1 |
| Piantadosi, S | 1 |
| Zeltzman, M | 1 |
| Wharam, M | 1 |
| Bogart, JA | 1 |
| Ungureanu, C | 1 |
| Ryu, S | 1 |
| Chung, CT | 1 |
| Zamkoff, KW | 1 |
| Sirohi, B | 1 |
| Powles, R | 1 |
| Treleaven, J | 1 |
| Mainwaring, P | 1 |
| Kulkarni, S | 1 |
| Pandha, H | 1 |
| Bhagwati, N | 1 |
| Horton, C | 1 |
| Singhal, S | 1 |
| Mehta, J | 1 |
| Hunault-Berger, M | 1 |
| Milpied, N | 1 |
| Bernard, M | 1 |
| Jouet, JP | 1 |
| Delain, M | 1 |
| Desablens, B | 1 |
| Sadoun, A | 1 |
| Guilhot, F | 1 |
| Casassus, P | 1 |
| Ifrah, N | 1 |
| Gururangan, S | 1 |
| Cokgor, L | 1 |
| Rich, JN | 1 |
| Edwards, S | 1 |
| Affronti, ML | 1 |
| Quinn, JA | 1 |
| Herndon, JE | 2 |
| Provenzale, JM | 1 |
| McLendon, RE | 1 |
| Tourt-Uhlig, S | 1 |
| Sampson, JH | 1 |
| Stafford-Fox, V | 1 |
| Zaknoen, S | 1 |
| Early, M | 1 |
| Friedman, AH | 1 |
| Friedman, HS | 1 |
| Maranhão, RC | 1 |
| Graziani, SR | 1 |
| Yamaguchi, N | 1 |
| Melo, RF | 1 |
| Latrilha, MC | 1 |
| Rodrigues, DG | 1 |
| Couto, RD | 1 |
| Schreier, S | 1 |
| Buzaid, AC | 1 |
| Johnson, RO | 1 |
| Metter, G | 1 |
| Wilson, W | 1 |
| Hill, G | 1 |
| Krementz, E | 1 |
| Costanzi, JJ | 1 |
| Presant, CA | 1 |
| Van Amburg, A | 1 |
| Klahr, C | 1 |
| Panella, TJ | 1 |
| Smith, DC | 1 |
| Schold, SC | 1 |
| Rogers, MP | 1 |
| Winer, EP | 1 |
| Fine, RL | 1 |
| Crawford, J | 1 |
| Trump, DL | 1 |
| Richards, JM | 1 |
| Bashir, R | 1 |
| Hochberg, FH | 1 |
| Linggood, RM | 1 |
| Hottleman, K | 1 |
| Mbidde, EK | 1 |
| Selby, PJ | 1 |
| Perren, TJ | 1 |
| Dearnaley, DP | 1 |
| Whitton, A | 1 |
| Ashley, S | 1 |
| Workman, P | 1 |
| Bloom, HJ | 1 |
| McElwain, TJ | 1 |
| Jagannath, S | 1 |
| Dicke, KA | 1 |
| Armitage, JO | 1 |
| Cabanillas, FF | 1 |
| Horwitz, LJ | 1 |
| Vellekoop, L | 1 |
| Zander, AR | 1 |
| Spitzer, G | 1 |
| Tchekmedyian, NS | 1 |
| Tait, N | 1 |
| Van Echo, D | 1 |
| Aisner, J | 1 |
| McClay, EF | 1 |
| Mastrangelo, MJ | 1 |
| Bellet, RE | 1 |
| Berd, D | 1 |
| Marsh, JC | 1 |
| DeConti, RC | 1 |
| Hubbard, SP | 1 |
| Fewer, D | 1 |
| Wilson, CB | 1 |
| Boldrey, EB | 1 |
| Enot, KJ | 1 |
| Powell, MR | 1 |
| Tormey, DC | 1 |
| Gailani, S | 1 |
| Leone, L | 1 |
| Cohen, SM | 1 |
| Greenspan, EM | 1 |
| Weiner, MJ | 1 |
| Kabakow, B | 1 |
| Jorgensen, EO | 1 |
| Malkasian, GD | 1 |
| Webb, MJ | 1 |
| Hahn, RG | 2 |
| Brunner, KW | 1 |
| Maurice, P | 1 |
| Sonntag, RW | 1 |
| Gottlieb, JA | 1 |
| Rivkin, SE | 1 |
| Spigel, SC | 1 |
| Hoogstraten, B | 1 |
| O'Bryan, RM | 1 |
| Delaney, FC | 1 |
| Singhakowinta, A | 1 |
| Kovach, JS | 1 |
| Moertel, CG | 1 |
| Schutt, AJ | 1 |
| Reitemeier, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I and Pharmacokinetics Study of SarCNU in Patients With Advanced Cancers[NCT00003703] | Phase 1 | 0 participants | Interventional | 1999-01-31 | Completed | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma[NCT00001270] | Phase 1 | 85 participants | Interventional | 1991-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carmustine and Thrombopenia
| Article | Year |
|---|---|
Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; | 1982 |
Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 1995 |
22 trials available for carmustine and Thrombopenia
| Article | Year |
|---|---|
SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Carmustine; Femal | 2003 |
Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Culture Techniques; | 2004 |
[Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-C | 2004 |
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Enzyme Inhibitors; | 2006 |
The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study.
Topics: Adult; Carmustine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration S | 1981 |
Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials a | 1982 |
Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
Topics: Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therap | 1982 |
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female; | 1982 |
Sequential therapy with dacarbazine and carmustine: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Drug Administr | 1994 |
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cycloph | 1996 |
Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1998 |
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Chem | 2000 |
Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies | 2001 |
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Femal | 1976 |
DTIC (NSC-45388) studies in the southwest oncology group.
Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Co | 1976 |
Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.
Topics: Adult; Aged; Alkaline Phosphatase; Carmustine; Drug Administration Schedule; Drug Evaluation; Drug R | 1992 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
Triple combination chemotherapy of disseminated melanoma.
Topics: Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Drug Combinati | 1972 |
Pilot study evaluating 1,3-bis(2-chloroethyl)-1-nitrosourea in the treatment of advanced ovarian carcinoma.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Injections, Intravenous; Ova | 1973 |
[On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
Topics: Carmustine; Chlorambucil; Cyclohexanes; Drug Resistance; Drug Synergism; Hodgkin Disease; Humans; Ni | 1972 |
23 other studies available for carmustine and Thrombopenia
| Article | Year |
|---|---|
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administra | 2010 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2012 |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2003 |
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Gr | 2003 |
Treatment of malignant gliomas in adults with BCNU plus metronidazole.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Female; Gliobl | 1984 |
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Drug Administration Schedule; Drug Evaluation; Drug Th | 1980 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
The influence of histologic subtype on toxicity and response to chemotherapy in non-hodgkin's lymphoma. An Eastern Cooperative Oncology Group Study utilizing the BCVP regimen.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; | 1983 |
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 1984 |
Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cycl | 1982 |
The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Ci | 1999 |
Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplas | 2000 |
Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Survival; Drug Carriers; E | 2002 |
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Ascites; Bone Neoplasms; Breast Neoplasms; Carmustine; | 1977 |
Sequential chemoimmunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Carmustine; Cispla | 1991 |
Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme.
Topics: Adult; Brain Diseases; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Combined Modality Ther | 1988 |
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Ther | 1988 |
High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1986 |
High-dose chemotherapy without autologous bone marrow transplantation in melanoma.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Di | 1986 |
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1987 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Carmustine; Cyclohexanes; Doxorubicin; Female; Humans | 1974 |
Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.
Topics: Adenocarcinoma; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopenia; Mal | 1974 |